HC Wainwright & Co. Reiterates Buy on Century Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Century Therapeutics (NASDAQ:IPSC) and maintained a $13 price target on the stock.
December 07, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Century Therapeutics has been given a reiterated Buy rating and a maintained price target of $13 by HC Wainwright & Co. analyst Mitchell Kapoor.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst like Mitchell Kapoor can instill confidence in investors and potentially lead to a positive short term impact on Century Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100